In-depth Focus from ATS 2022: PAH

Using Electronic Health Records to Predict Mortality Post COPD Hospitalization

By

Sheila Jacobs

Publish Date May 9, 2022

For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?

Long-Term Sotatercept Efficacy in Pulmonary Arterial Hypertension

By

Ron Goldberg

Publish Date May 31, 2022

An open-label extension study of the PULSAR trial evaluated sotatercept treatment of patients with pulmonary arterial hypertension over 12 to 18 months.

Socioeconomic Factors Linked to Treatment Delays in Veterans with PAH

By

Ron Goldberg

Publish Date May 31, 2022

Are delays in treatment for pulmonary arterial hypertension the cause of the poorer PAH outcomes seen among individuals in socially disadvantaged groups?

Long-Term Safety, Tolerability of Ralinepag in Pulmonary Arterial Hypertension

By

Ron Goldberg

Publish Date May 31, 2022

Findings of a long-term study on the safety and efficacy of ralinepag for pulmonary arterial hypertension are consistent with earlier clinical trial findings.

Does Midodrine Help Patients Tolerate Pulmonary Arterial Hypertension Therapy?

By

Pam Brick

Publish Date May 31, 2022

Can midodrine effectively stabilize blood pressure in patients with pulmonary arterial hypertension, thus enabling them to increase their PAH medication dosage?

Impaired Gas Exchange During Submaximal Exercise and Clinical Worsening in PAH

By

Pam Brick

Publish Date May 31, 2022

In patients with pulmonary arterial hypertension, is abnormal pulmonary gas exchange during submaximal exercise associated with greater risk of clinical worsening events?

Are Peripheral Arterial Dysfunction and Stiffness Associated With PAH?

By

Pam Brick

Publish Date May 31, 2022

How is PAH severity related to peripheral endothelial dysfunction and arterial stiffness, and how does PAH treatment affect these variables?